A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

被引：5
|
作者：
Abali, Huseyin
Yalcin, Suayib
Onal, Huseyin Cem
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye
Mertsoylu, Huseyin
Artac, Mehmet
Camci, Celalettin
Karabulut, Bulent
Basal, Fatma Bugdayci
Budakoglu, Burcin
Sendur, Mehmet Ali Nahit
Goktas, Burce
Ozdener, Fatih
Calisgan, Arzu
机构：
[1] Acibadem Univ, Adana, Turkey
[2] Hacettepe Univ, Ankara, Turkey
[3] Baskent Univ, Radiat Oncol, Adana, Turkey
[4] Marmara Univ, Istanbul, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Ankara, Turkey
[7] Baskent Univ, Adana, Turkey
[8] Necmettin Erbakan Univ, Meram Sch Med, Konya, Turkey
[9] Gaziantep Univ, Gaziantep, Turkey
[10] Ege Univ, Izmir, Turkey
[11] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey
[12] Roche Pharmaceut, Istanbul, Turkey
[13] Medstats Consulting, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS182
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Assessment of HER2 status from an epidemiology study in tumor tissue samples of gastric and gastro-esophageal junction cancer: Results from the french cohort of the HER-EAGLE study
    Monges, Genevieve
    Terris, Benoit
    Chenard, Marie-Pierre
    Penault-Llorca, Frederique
    Beauclair, Sophie
    Bibeau, Frederic
    Emile, Jean-Francois
    Volant, Alain
    Doucet, Laurent
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G).
    Sukawa, Yasutaka
    Makiyama, Akitaka
    Esaki, Taito
    Hirano, Gen
    Komoda, Masato
    Kashiwada, Tomomi
    Kawada, Junji
    Hosokawa, Ayumu
    Tsuda, Takashi
    Tsuji, Akihito
    Moriwaki, Toshikazu
    Tanioka, Hiroaki
    Yonesaka, Kimio
    Nishio, Kazuto
    Nosho, Katsuhiko
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Oxaliplatin and capecitabine (XELOX) plus toripalimab as perioperative treatment for locally advanced gastric or gastro-esophageal junction adenocarcinoma (Neo-Capture): A single-arm, phase 2 study.
    Jiang, Zhichao
    Xie, Yibin
    Wang, Bingzhi
    Zhu, Yongjian
    Ke, Yan
    Zhang, Wen
    Sun, Yongkun
    Li, Yin
    Wang, Chengfeng
    Zhao, Dongbing
    Tian, Yantao
    Zhou, Ai-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16002 - E16002
  • [24] T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.
    Esaki, Taito
    Makiyama, Akitaka
    Kashiwada, Tomomi
    Hosokawa, Ayumu
    Kawada, Junji
    Moriwaki, Toshikazu
    Horie, Yoshiki
    Satake, Hironaga
    Shinozaki, Katsunori
    Ishida, Hiroyasu
    Tanioka, Hiroaki
    Tsukuda, Hiroshi
    Uchino, Keita
    Nishikawa, Kazuhiro
    Sukawa, Yasutaka
    Yamanaka, Takeharu
    Nakamura, Shinichiro
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [25] End-of-study analysis from JACOB: A phase III study of pertuzumab (P) plus trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)
    Tabernero, J.
    Hoff, P. M.
    Shen, L.
    Ohtsu, A.
    Shah, M. A.
    Siddiqui, A.
    Heeson, S.
    Wu, H.
    Restuccia, E.
    Kang, Y-K.
    ANNALS OF ONCOLOGY, 2020, 31 : S900 - S901
  • [26] Adenocarcinomas of the gastro-esophageal junction: A comparative study of the gastric cardia and the esophagus with respect to cyclooxygenase-2 expression
    Buskens, C
    Sivula, A
    Westerterp, M
    Offerhaus, J
    Ristimaki, A
    Van Lanschot, J
    GASTROENTEROLOGY, 2003, 124 (04) : A117 - A118
  • [27] Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Fernando Rivera
    C. Romero
    P. Jimenez-Fonseca
    M. Izquierdo-Manuel
    A. Salud
    E. Martínez
    M. Jorge
    V. Arrazubi
    J. C. Méndez
    P. García-Alfonso
    M. Reboredo
    J. Barriuso
    N. Muñoz-Unceta
    R. Jimeno
    C. López
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1175 - 1181
  • [28] Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Rivera, Fernando
    Romero, C.
    Jimenez-Fonseca, P.
    Izquierdo-Manuel, M.
    Salud, A.
    Martinez, E.
    Jorge, M.
    Arrazubi, V.
    Mendez, J. C.
    Garcia-Alfonso, P.
    Reboredo, M.
    Barriuso, J.
    Munoz-Unceta, N.
    Jimeno, R.
    Lopez, C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1175 - 1181
  • [29] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [30] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    BMC Cancer, 18
12345